Efficacy and safety of fexagratinib (Fexa) in Chinese patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) harboring FGF receptor (FGFR) genetic alterations.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Fudan University Shanghai Cancer Center, Union Hospital, The Affiliated Yongchuan Hospital of Chongqing Medical University, Shandong University, Qilu Hospital of Shandong University, Anhui Provincial Hospital, Liaoning Cancer Hospital & Institute, Second Xiangya Hospital of Central South University, Hunan Cancer Hospital, Shanghai First People's Hospital, Henan Cancer Hospital, Wuhan Union Hospital, Huazhong University of Science and Technology, Army Medical University, Hainan General Hospital, Third Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Fujian Medical University, Peking University Cancer Hospital, First Hospital of Shijiazhuang
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4407698987